Morgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc
|
|
- Berniece Beasley
- 5 years ago
- Views:
Transcription
1 Morgan Stanley CEOs Unplugged January 3, 2008 Matthew Emmens, CEO Shire plc
2 Introduction Strategy on track Excellent third quarter results Strong product sales reflecting good results and successful product launches across all areas of our business Upgrading revenue growth guidance to at least 30% (previous guidance: at least 25%) 2
3 How the Shire strategy is working 6 launches in past two years: FOSRENOL, ELAPRASE, DAYTRANA, LIALDA, VYVANSE, DYNEPO 100% track record of approvals or approvables in past four years Strong intellectual property for key growth driving products Focus on orphan drugs and specialist products fulfilling unmet needs Global expansion into new markets (South America, Russia, Mexico, Australia, Japan) Revenue growth 2006 = 12% 2007 latest published guidance recently upgraded to at least 30% 3
4 Strong market exclusivity for growth drivers VYVANSE LIALDA^ FOSRENOL ELAPRASE* 2013 EU DYNEPO Patent Life Regulatory Exclusivity ^ Currently difficult generic approval pathway for locally acting drugs *Orphan Drug 4
5 VYVANSE Launch update
6 VYVANSE is positioned as a new class of ADHD medication not just a replacement to AXR 6
7 Key attributes to support VYVANSE as an NCE in a new class The first Pro-drug Stimulant Consistent time to maximum concentration of d-amphetamine from patient to patient Significant efficacy throughout the day, even at 6:00 PM Adverse event profile that is mild to moderate in severity and incidence decreases over time Significantly lower abuse related liking effect than an equivalent oral dose of d-amphetamine 7 5
8 VYVANSE TRxs are growing and separating from coupon redemptions showing that patients are refilling Weekly Coupon Redemptions Weekly RX Data Jul 20-Jul 3-Aug 17-Aug 31-Aug 14-Sep 28-Sep 12-Oct 26-Oct 9-Nov 23-Nov 7-Dec Every redeemed coupon is accompanied by an Rx Only one coupon (30 capsules) can be redeemed per patient Over 500,000 Rx written since launch SOURCE: IMS Rx & PSKW 8
9 VYVANSE patients reported coming from ADDERALL XR and other brands 10,045 patients started on VYVANSE have enrolled and completed baseline surveys At baseline, 84% had used a prescription for ADHD prior to VYVANSE 4% 10% 16% No Prior 11% 6% 14% 39% Adderall XR Concerta Daytrana Focalin XR Strattera Other N = 10,045 Source: VYVANSE New Start Patient Experience program 9
10 Among patients who switched from ADDERALL XR to VYVANSE, 75% reported further improvement in their most bothersome symptom Change in main symptoms after 40 Days with VYVANSE Worse 4% Better 75% About the Same 21% n=455 Source: VYVANSE New Start Patient Experience program including over 10,000 patients surveyed of whom 39% were formerly ADDERALL XR users. Among these patients, more than half reported that they still experienced the most bothersome symptoms of ADHD. Notes: Most bothersome symptoms reported: First: inattention, second: hyperactivity and third: impulsiveness. 10
11 8 out of 10 parents reported they intend to continue their child on VYVANSE after switching from ADDERALL XR Intent to Continue VYVANSE After 40 Days 16% 4% Yes Maybe No 80% N=455 Source: VYVANSE New Start Patient Experience program 11
12 VYVANSE is taking market share from all products in the ADHD category, not just ADDERALL XR 5.0% 4.0% Rx Share Change by ADHD Product Since VYVANSE Launch 5.20% 3.0% 2.0% 1.0% 0.0% 6/22 6/29 7/6 7/13 7/20 7/27 8/3 8/10 8/17 8/24 8/31 9/7 9/14 9/21 9/28 10/510/1210/1910/2611/2 11/911/1611/2311/3012/7-1.0% -2.0% Adderall XR Vyvanse Concerta Strattera Generic MPH Generic AMPH -1.80% SOURCE: IMS NGPS - Universe 12
13 Back to School is not a one-two week event; It runs through October ADHD Market Weekly TRx volume 2007 Actual through 11/16/07 850, ,000 Back to School 750, ,000 TRxs 650, , , , ,000 Vyvanse Launched July 2007 Thanksgiving Labor Day Holiday Season Wk 1 Wk 4 Wk 7 Wk 10 Wk 13 Wk 16 Wk 19 Wk 22 Wk 25 Wk 28 Wk 31 Wk 34 Wk 37 Wk 40 Wk 43 Wk 46 Wk 49 Wk 52 ADHD ADHD
14 Managed Care update Coverage is progressing as planned: 6-9 month post-launch review period on adding new products to formulary is common Early success 3 of top 6 targeted MCO s have added VYVANSE with preferred status Negotiations with numerous plans are progressing Parity with ADDERALL XR formulary status expected by 18 months 14
15 VYVANSE Summary VYVANSE rapid launch uptake 5.2% market share as of week 12/7/07 Tracking in line with the industry s best successor molecule launches Patients starting on coupons are refilling Rxs Back to school is not a one-two week event, but lasts a few months Physicians and Patients are providing very positive feedback on their clinical experience with VYVANSE Managed Care coverage is progressing as planned VYVANSE has tremendous growth potential beyond 2009 Very strong IP Europe Potential for other indications SOURCE: IMS NGPS as at November 16,
16 LIALDA Launch update
17 LIALDA s growth continues with 7.5% monthly TRx share and 9.7% NRx monthly share in November NRx Volume TRx Volume NRx Share TRx Share Rx Volume 25,000 20,000 15,000 10,000 5,000 0 March April May June July Aug Sep Oct Nov 10.0% 9.0% 8.0% 7.0% 6.0% 5.0% 4.0% 3.0% 2.0% 1.0% 0.0% NRx Volume 722 3,143 5,340 5,896 6,268 7,689 7,594 8,744 8,571 TRx Volume 725 3,427 7,020 9,258 11,583 14,452 15,429 18,575 19,201 NRx Share 0.8% 3.7% 5.8% 6.6% 6.9% 8.1% 9.0% 9.3% 9.70% TRx Share 0.3% 1.4% 2.7% 3.6% 4.4% 5.4% 6.3% 6.9% 7.50% Source: IMS Monthly NGPS November
18 Total Shire GI monthly share reached 23.8% of 5-ASA Market Shire GI Portfolio Oral 5-ASA Monthly TRx Share 25.0% Pentasa Lialda Shire Portfolio 23.8% 20.0% 15.0% 16.9% 10.0% 5.0% 6.9% 0.0% Jan Feb Mar Apr May Jun Jul Aug Sep Oct Source: IMS Monthly NPA (NGPS) Restated Feb-June 2007 Data Oral 5-ASA Market Definition: Lialda, Pentasa, Asacol, Colazal and Dipentum 18
19 LIALDA s prescriptions are being generated from both new patients and conversions from other brands LIALDA June 2007 Patient Source of Business New Patients, 26% Switches, 23% Add On, 2% Restart, 2% Continuing, 48% Source: Verispan Patient Parameters Source of Business, June
20 Recent events
21 Expansion of Human Genetic Pipeline through inlicensing agreement with Amicus Therapeutics Inc. Acquisition of ex-us rights for: AMIGAL, Fabry disease (Phase 2) PLICERA, Gaucher disease (Phase 2) AT2220, Pompe disease (Phase 1) Financial terms of the license are geared to the successful development and commercialization of the products $50m upfront and up to $390m of development and sales-based milestones and; Royalties on net sales of the products, with tiered, double digit royalty rates Oral therapies based on novel chaperone technology for Lysosomal Storage Disorders: This technology has been applied to various defective enzymes as a result of improper folding. Pharmacological chaperone technology uses small molecules that selectively bind to and stabilize proteins in cells. This leads to improved protein folding into its proper threedimensional shape. The re-folded enzyme can then be trafficked to the specific location in the cell to perform its intended biological function. 21
22 Concluding Remarks 2007 guidance upgraded as revenue growth accelerates revenue growth to be at least 30% for 2007 (previous guidance: at least 25%) Excellent Q3 results Successful ongoing launches Continuing to demonstrate our ability to execute VYVANSE enthusiastic response from physicians and caregivers ELAPRASE rapid uptake in US and EU LIALDA growth continues 9.7% share of NRx as of week 12/7/07 FOSRENOL strong start in Europe DYNEPO launched in Q1 2007, good reception Good progress in strengthening our R&D pipeline In-licensing agreement with Amicus Therapeutics Inc. 3 oral treatments for: Gaucher, Fabry and Pompe disease JUVISTA license agreement with Renovo Positive Phase 2 clinical trial results SOURCE: IMS NGPS as at November 2,
23 Additional information and Backup slides
24 Total Revenues Q3 07 Q3 06 Growth $m $m % Product Sales % Royalties Other Revenues Total Revenues % Q3 07 Q3 06 Growth $m $m % Product Sales 77% % (excl. new launches) ELAPRASE LIALDA FOSRENOL US FOSRENOL EU 23% VYVANSE DAYTRANA DYNEPO Product Sales 100% % Product Sales from New Launches (%) % Q1 Q2 Q
25 Major Product Sales Q3 07 Q3 06 Sales US RX* $m $m Growth Growth ADDERALL XR % 3% VYVANSE n/a n/a DAYTRANA % 64% PENTASA % 2% LIALDA n/a n/a ELAPRASE n/m n/a REPLAGAL % n/a FOSRENOL % 0% CARBATROL % -5% XAGRID % n/a * Source: IMS Data 25
26 VYVANSE Gross to Net Sales (Q3 2007) Q3 TRx ('000)* $m Notes Sales Demand Price per TRx = 28.3 (tablets per TRx) x $3.41 (price per tablet) Restocking 10.2 Underlying gross sales % Sales coupons (12.3) 39% Wholesaler discounts & rebates (8.2) 27% 66% Q2 deferred revenue sales 55.9 Add Q3 deferred sales 1.9 Less Q3 sales demand (20.9) Deferred revenue at 9/30/ Net Sales % Sales deductions will trend towards a long term rate of approximately 28%. *per IMS 26
27 DAYTRANA Gross to Net Sales (Q3 2007) Q3 TRx ('000)* $m Notes Sales Demand Price per TRx = 29.8 (patches per TRx) x $3.98 (price per patch) Destocking (0.1) Underlying gross sales % Sales coupons (3.9) 18% Returns (4.0) 18% 56% Coupon expense to moderate at 10% in Voluntary market withdrawal. This is a one off charge for Q3 Wholesaler discounts and rebates (4.3) 20% Net Sales % *per IMS Sales deductions are expected to trend towards a long term rate of approximately 25%. 27
28 Royalties Q3 07 Q3 06 Growth $m $m (%) 3TC % * ZEFFIX % ** Other *** % Total % *Foreign exchange movements have contributed +4% to reported growth **Foreign exchange movements have contributed +6% to reported growth ***Includes REMINYL/RAZADYNE 28
29 Financial Ratios (% of net product sales) (on a non-gaap basis) Q3 07 Q3 06 YTD 07 FY 06 COGS 14% 14% 14% 13% Gross margin 86% 86% 86% 87% R&D 19% 19% 18% 20% SG&A 46% 54% 47% 52% Operating EBITDA (1) 21% 14% 22% 16% Operating EBITDA margin (% Total Revenue) 29% 26% 31% 28% (1) Excluding royalties This slide contains non GAAP financial measures. They exclude intangible asset amortization in respect of intellectual property charges, the accounting impact of share-based compensation and the effect of certain cash and non-cash items, both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire s business. 29
30 Net Income/EPS Q3 07 Q3 06 Growth YTD 07 Net income ($m) (%) - GAAP Adjustments 91.5 (1.5) - Non GAAP (1) (2) % EPS - ADS (diluted) - GAAP 18.9c 51.3c - Non GAAP (1) 66.3c (2) 50.4c 32% 200.4c (1) These are non GAAP financial measures. They exclude intangible asset amortization charges, the accounting impact of share-based compensation and the effect of certain cash and non-cash items, both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire s business. (2) The Q3 Non GAAP tax rate was 15% (see slide 21) compared to a guidance rate of 26%. This low tax rate was primarily due to a higher level of tax deductible expenditure than forecast in high-tax territories (principally the US) and reductions in specific tax liabilities relating to tax reviews and tax filings which have now been finalised. The impact of this credit was to increase Non GAAP income by approximately $15m and Non GAAP earnings per ADS by approximately 7c. 30
31 EPS Reconciliation Q3 07 Q3 07 Q3 06 Q3 06 $m cents/ads $m cents/ads Net income for diluted EPS (ADS) c c Cost of product sales fair value adjustment c In-licensing payments c c Gain on disposal of product rights (7.1) (3.6c) (63.0) (37.5c) Legal settlement provision c - - Intangible asset amortization c c SFAS 123R effect c c Taxes on above adjustments (46.2) (23.7c) c Non GAAP net income / EPS (ADS) c c 31
32 Cash flow Q $ in millions Cash generation Renovo -30 Fixed asset purchases -26 Asset Sales Net tax/interest -61 Product Milestones Other Financing Cash at 30/6/ Cash outflow Q3 07 (33) Cash at 30/9/07 (1) (2) 605 Convertible debt (1,100) Net debt at 30/9/07 (495) (1) Shire s balance of cash and cash equivalents at 30 Sept 2007 includes $42m of restricted cash and is available to finance payments due to TKT dissenting shareholders (provision at 30 Sept 2007 of $473m) (2) Shire has a revolving credit facility of $1.2bn which was undrawn at 30 Sept 2007 Net cash outflow for Q :
33 Updated FY 2007 Guidance Q3 07 YTD 07 Updated Q2 Actual Actual FY Guidance FY Guidance Revenue growth 35% 32% > 30% > 25% R&D - GAAP ($m) Less SFAS 123R (3.3) (8.8) Noven - (5.9) Renovo (75.0) (75.0) R&D - Non GAAP ($m) $365m to $375m $340m to $360m SG&A - GAAP ($m) Less SFAS 123R (7.5) (22.7) Legal settlement provision (27.0) (27.0) SG&A - Non GAAP ($m) $955m to $975m $930m to $960m 33
34 Updated FY 2007 Guidance (cont.) Q3 07 YTD 07 Updated Q2 Actual Actual FY Guidance FY Guidance D&A - GAAP ($m) Less amortization (31.1) (64.0) Up 70% Up 80% Depn - Non GAAP ($m) Up 30% Up 20% Tax charge (credit) - US GAAP (23.2) 43.9 Less non GAAP adjustments Non GAAP Charge Non GAAP-Income before tax Effective Tax rate 15% 22% Low 20%'s 26% 34
35 VYVANSE demonstrated strong efficacy in Adults with ADHD in a very large Phase III study The study was a double-blind, placebo-controlled, 4-week study with forced dose escalation in 420 adult subjects aged 18 to 55 years with moderate to severe symptomatic ADHD All VYVANSE doses (30, 50, or 70 mg/d) were highly effective compared with placebo, as shown by ADHD-RS-IV (the primary endpoint) Significant improvements in ADHD symptoms were observed within the first week of treatment Adverse event profile was similar to that seen with other ADHD trials in adults. A/Es were mild to moderate in severity and incidence decreased over time VYVANSE did not worsen sleep quality 35 5
Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationFirst Quarter Results to March 31, Shire plc April 25, 2007
First Quarter Results to March 31, 2007 Shire plc April 25, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationThird Quarter Results to September 30, 2009
Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals
More informationCowen Healthcare Conference Shire plc
Cowen Healthcare Conference Shire plc Michael Cola President, Specialty Pharmaceuticals THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationSG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc
SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationSecond Quarter Results to June 30, 2010
Second Quarter Results to June 30, 2010 Shire plc August 4, 2010 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals Sylvie
More informationShire plc. Matthew Emmens, CEO
Shire plc Matthew Emmens, CEO THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements
More informationBank of America Merrill Lynch Global Healthcare Conference 2011
Bank of America Merrill Lynch Global Healthcare Conference 2011 September 14, 2011 Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead better
More informationFourth quarter and full year results to December 31, 2012
Fourth quarter and full year results to December 31, 2012 Shire plc February 14, 2013 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Flemming Ornskov Chief Executive
More informationCSFB Healthcare Conference November 16, 2006
CSFB Healthcare Conference November 16, 2006 Matthew Emmens, CEO Shire plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 "SAFE HARBOR" STATEMENT UNDER THE PRIVATE
More informationFull Year and Fourth Quarter Results ended 31 December Shire Pharmaceuticals Group plc
Full Year and Fourth Quarter Results ended 31 December 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationMorgan Stanley CEOs Unplugged Conference January 3, 2007
Morgan Stanley CEOs Unplugged Conference January 3, 2007 Matthew Emmens, CEO Shire plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 "SAFE HARBOR" STATEMENT UNDER
More informationShire Pharmaceuticals Group plc
Third Quarter Results Period ending 30 September 2003 5 November 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 8, 2011 Sylvie Grégoire President, Human Genetic Therapies Our purpose We enable people with life-altering conditions to lead better lives THE SAFE HARBOR STATEMENT
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationBank of America Merrill Lynch Global Healthcare Conference 2012
Bank of America Merrill Lynch Global Healthcare Conference 2012 Shire plc September 12, 2012 Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead
More informationJP Morgan H&Q Healthcare Conference January 7, Shire Pharmaceuticals Group plc
JP Morgan H&Q Healthcare Conference January 7, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 The statements made during
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationNasdaq: SNTS. January 11, 2010
Nasdaq: SNTS January 11, 2010 Safe Harbor This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationWELCOME TO ACTELION S AGM 2015
WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationZegerid Capsules 20 mg and 40 mg Zegerid Powder for Oral Suspension 20 mg and 40 mg
Nasdaq: SNTS Safe Harbor This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our management. The
More informationMarket Potential for MDX Alcobra Investor Breakfast July 15, 2014
Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More information4Q and Full Year 2017 Financial Results Call February 7, 2018
4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationPharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011
ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE
More informationAlcobra Ltd. (NASDAQ:ADHD) June 2016
Alcobra Ltd. (NASDAQ:ADHD) June 2016 1 1 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking statements
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationAlcobra Ltd. (NASDAQ:ADHD) June Dr. Yaron Daniely President & CEO
Alcobra Ltd. (NASDAQ:ADHD) June 2015 Dr. Yaron Daniely President & CEO 1 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationInsulin Pens - Medical Devices Pipeline Assessment, 2016
Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationTotal Face Group Limited
Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationOncolytics Biotech Inc. Announces Third Quarter 2010 Results
November 10, 2010 Oncolytics Biotech Announces Third Quarter 2010 Results CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationNASDAQ: FHCO 2016 Annual Meeting
NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationQ1 FY02/2014 Results
Hisamitsu Pharmaceutical Co., Inc. FY02/2014 Results This presentation material contains information that constitutes forwardlooking statements. Such forward-looking statements are not guarantees of future
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More information27 September Interim results for the six months ended 30 June 2018
27 September 2018 Interim results for the six months ended 30 June 2018 Disclaimer 2 Neither this presentation nor any verbal communication shall constitute, or form part of, any offer, invitation or inducement
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationMerrill Lynch Global Healthcare Conference February 4, Shire Pharmaceuticals Group plc
Merrill Lynch Global Healthcare Conference February 4, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 995 The statements
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More information